Investigated for use/treatment in psoriasis and psoriatic disorders and crohn's disease.
- Mechanism
- Curator reviewed
Tumor necrosis factor (TNF) is a proinflammatory cytokine that plays a pivotal part in the pathogenesis of Crohn’s disease (CD).1 A number of anti-TNF therapies have been developed for the treatment of CD. Onercept is a recombinant form of the soluble human p55 TNF-greek small letter alpha receptor (also known as TNF-binding protein 1) produced by recombinant DNA technology. Its putative mechanism of action involves neutralizing the effects of TNF by the formation of high-affinity complexes.
- Primary indication
- Investigated for use/treatment in psoriasis and psoriatic disorders and crohn's disease.Curator reviewed
- Also known as
- R-HTBP-1
Resolves to
What you can answer from here — as of June 15, 2026
Which drugs share a target with Onercept, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account